

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Imagion Biosystems Limited
<b>ABN</b> 42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brett Mitchell
<b>Date of last notice</b>	28 June 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"><li>Mr Brett Mitchell and Mrs Michelle Mitchell &lt;Lefthanders Super Fund A/C&gt; (Trustee and Beneficiary)</li><li>Mr Brett Mitchell and Mrs Michelle Mitchell &lt;Mitchell Spring Family A/C&gt; (Trustee and Beneficiary)</li></ol>
<b>Date of change</b>	22 August 2024
<b>No. of securities held prior to change</b>	1. 520,908 Ordinary Shares
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	<ol style="list-style-type: none"><li>625,000 Performance Rights</li><li>625,000 Performance Rights</li></ol>
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 520,908 Ordinary Shares 625,000 Performance Rights (expiring 22 August 2028), comprising of: <ol style="list-style-type: none"> <li>a. 187,500 Class A (Share price of at least \$0.10 over 20 consecutive trading days);</li> <li>b. 187,500 Class B (Market capitalisation of at least \$7.5 million over 20 consecutive trading days);</li> <li>c. 250,000 Class C (Market capitalisation of at least \$12.5 million over 20 consecutive trading days).</li> </ol> </li> <li>2. 625,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: <ol style="list-style-type: none"> <li>a. 187,500 Class A (Share price of at least \$0.10 over 20 consecutive trading days);</li> <li>b. 187,500 Class B (Market capitalisation of at least \$7.5 million over 20 consecutive trading days);</li> <li>c. 250,000 Class C (Market capitalisation of at least \$12.5 million over 20 consecutive trading days).</li> </ol> </li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Appendix 3Y reflects changes following the issue of Performance Rights approved by shareholder at the 22 August 2024 Extraordinary General Meeting.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.